TScan Therapeutics Merges with Enliven Therapeutics, Renames Company
Ticker: TCRX · Form: 8-K · Filed: Dec 26, 2024 · CIK: 1783328
| Field | Detail |
|---|---|
| Company | Tscan Therapeutics, Inc. (TCRX) |
| Form Type | 8-K |
| Filed Date | Dec 26, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $4.00, $30.0 m, $29.8 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, acquisition, biotech, name-change
TL;DR
TScan is now Enliven Therapeutics after merger approval; new leadership takes over.
AI Summary
On December 26, 2024, TScan Therapeutics, Inc. announced the closing of its previously disclosed merger agreement with Enliven Therapeutics, Inc. The transaction was approved by TScan's stockholders on December 23, 2024. As a result of the merger, TScan Therapeutics, Inc. will be renamed Enliven Therapeutics, Inc. and will continue to operate under the leadership of Enliven's management team.
Why It Matters
This merger signifies a strategic consolidation in the biotechnology sector, potentially leading to a combined entity with enhanced capabilities and a broader pipeline for developing novel therapies.
Risk Assessment
Risk Level: medium — Mergers and acquisitions inherently carry integration risks, potential pipeline shifts, and market reception uncertainties.
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Registrant
- Enliven Therapeutics, Inc. (company) — Acquiring entity/Renamed entity
- December 26, 2024 (date) — Date of report and closing of merger
- December 23, 2024 (date) — Date of stockholder approval
FAQ
What is the new name of the combined company?
The combined company will be renamed Enliven Therapeutics, Inc.
When did TScan Therapeutics' stockholders approve the merger?
TScan Therapeutics' stockholders approved the merger on December 23, 2024.
Who will lead the combined company?
The combined company will continue to operate under the leadership of Enliven's management team.
What is the effective date of the merger closing?
The merger closed on December 26, 2024.
What was the previous name of the company that will now be known as Enliven Therapeutics, Inc.?
The previous name was TScan Therapeutics, Inc.
Filing Stats: 1,201 words · 5 min read · ~4 pages · Grade level 12.2 · Accepted 2024-12-26 07:30:30
Key Financial Figures
- $0.0001 — which registered Voting Common Stock, $0.0001 par value per share TCRX The Nasdaq
- $4.00 — Common Stock"), at a purchase price of $4.00 per warrant with an exercise price of $
- $30.0 m — gregate gross proceeds of approximately $30.0 million, before deducting offering expens
- $29.8 million — ffering expenses, will be approximately $29.8 million. The Company will receive nominal proce
Filing Documents
- d861236d8k.htm (8-K) — 32KB
- d861236dex41.htm (EX-4.1) — 68KB
- d861236dex51.htm (EX-5.1) — 9KB
- d861236dex101.htm (EX-10.1) — 119KB
- g861236g1225091710379.jpg (GRAPHIC) — 3KB
- 0001193125-24-284671.txt ( ) — 413KB
- tcrx-20241226.xsd (EX-101.SCH) — 3KB
- tcrx-20241226_lab.xml (EX-101.LAB) — 18KB
- tcrx-20241226_pre.xml (EX-101.PRE) — 11KB
- d861236d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are based on the Company's beliefs and assumptions and on information currently available to the Company on the date of this Current Report. These forward-looking statements involve substantial risks and uncertainties. Any statements in this Current Report on Form 8-K other than statements of historical fact, including statements about the Company's future expectations, plans and prospects, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company's strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's financial and operating results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including the factors discussed in the "Risk Factors" section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company's views only as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law even if new information becomes available in the future. SIGNATURE Pursuant to the requirements of the Securit